PMID- 38462613
OWN - NLM
STAT- MEDLINE
DCOM- 20240312
LR  - 20240313
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 24
IP  - 1
DP  - 2024 Mar 11
TI  - Short-term effect of intravitreal dexamethasone implant in refractory diabetic 
      macular edema.
PG  - 113
LID - 10.1186/s12886-024-03341-9 [doi]
LID - 113
AB  - PURPOSE: To evaluate the short-term effects (hours-days) of intravitreal 
      dexamethasone implant (IDI) in eyes with diabetic macular edema (DME) refractory 
      to anti-vascular endothelial growth factor (VEGF) injections. METHODS: This was a 
      prospective, single-arm, interventional clinical series. Eyes with DME and 3-9 
      injections of ranibizumab without a good response were included. Patients 
      underwent a single IDI. Best-corrected visual acuity (BCVA) measurement, complete 
      ophthalmic evaluation, and spectral-domain optical coherence tomography (SD-OCT) 
      were performed at baseline, 2 h, 3 h, 24 h, 7 days, and 1 month. The main 
      outcomes were change in central retinal thickness (CRT) on SD-OCT and BCVA. 
      RESULTS: Fifteen eyes of 15 patients were included. Mean CRT decreased after 
      treatment from 515.87 microm +/- 220.00 microm at baseline to 489.60 microm +/- 176.53 microm after 
      2 h (p = 0.126), and 450.13 microm +/- 163.43 at 24 h (p = 0.006). Change in BCVA was 
      from 0.85 +/- 0.44 logMAR baseline to 0.58 +/- 0.37 log MAR at 1 month (p = 0.003). 
      CONCLUSIONS: Eyes treated with IDI showed significant decrease in CRT detectable 
      1 day after injection. In some patients, the effect could be observed 3 h 
      post-implantation. TRIAL REGISTRATION: Clinicaltrials.gov NCT05736081 . 
      Registered 20 February 2023, Retrospectively registered.
CI  - (c) 2024. The Author(s).
FAU - Moreno, Jazmin Baca
AU  - Moreno JB
AD  - Retina Department, Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico 
      City, Mexico.
FAU - Medina, David Berrones
AU  - Medina DB
AD  - Retina Department, Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico 
      City, Mexico.
FAU - Rosellon-Escobar, Maria Fernanda
AU  - Rosellon-Escobar MF
AD  - Retina Department, Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico 
      City, Mexico.
AD  - School of Medicine and Health Sciences, Tecnologico de Monterrey, Mexico City, 
      Mexico.
FAU - Garcia-Aguirre, Jose Gerardo
AU  - Garcia-Aguirre JG
AD  - Retina Department, Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico 
      City, Mexico. jerry_gar_md@yahoo.com.
AD  - School of Medicine and Health Sciences, Tecnologico de Monterrey, Mexico City, 
      Mexico. jerry_gar_md@yahoo.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT05736081
PT  - Journal Article
DEP - 20240311
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 0 (Glucocorticoids)
RN  - 0 (Drug Implants)
SB  - IM
MH  - Humans
MH  - *Macular Edema/diagnosis/drug therapy/etiology
MH  - Dexamethasone
MH  - Glucocorticoids
MH  - *Diabetic Retinopathy/complications/diagnosis/drug therapy
MH  - Prospective Studies
MH  - Intravitreal Injections
MH  - Drug Implants
MH  - Tomography, Optical Coherence
MH  - *Diabetes Mellitus
PMC - PMC10926656
OTO - NOTNLM
OT  - Diabetic macular edema
OT  - Intravitreal dexamethasone
OT  - Ozurdex
COIS- Jose Gerardo Garcia-Aguirre: Alcon C, L; Allergan C, L; Bayer C, L; Heidelberg 
      Engineering L; Liomont C; Nidek L; Novartis C, L; Roche Genetech L, S; Zeiss L 
      The rest of the author declare that they have no competing interests.
EDAT- 2024/03/11 06:43
MHDA- 2024/03/12 11:43
PMCR- 2024/03/11
CRDT- 2024/03/11 00:13
PHST- 2023/11/29 00:00 [received]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/03/12 11:43 [medline]
PHST- 2024/03/11 06:43 [pubmed]
PHST- 2024/03/11 00:13 [entrez]
PHST- 2024/03/11 00:00 [pmc-release]
AID - 10.1186/s12886-024-03341-9 [pii]
AID - 3341 [pii]
AID - 10.1186/s12886-024-03341-9 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2024 Mar 11;24(1):113. doi: 10.1186/s12886-024-03341-9.